Antibiotic susceptibility of group A streptococci: a 6-year follow-up study

Area of Science:

• Microbiology
• Infectious Diseases
• Antimicrobial Resistance

Background:

• Group A Streptococcus (GAS) is a significant human pathogen.
• Antimicrobial susceptibility patterns are crucial for effective treatment.
• Previous studies in 1987 indicated GAS susceptibility to beta-lactams.

Purpose of the Study:

• To determine the in vitro susceptibility patterns of Group A Streptococcus isolates over a six-year period.
• To assess changes in antimicrobial resistance since the last hospital study in 1987.

Main Methods:

• Retrospective analysis of GAS isolates collected over six years.
• In vitro antimicrobial susceptibility testing using standard methods.
• Evaluation of resistance to penicillin, beta-lactam agents, erythromycin, clindamycin, tetracycline, and ofloxacin.

Main Results:

• All GAS isolates remained highly susceptible to penicillin and other tested beta-lactam agents.
• Observed resistance to erythromycin, clindamycin, tetracycline, and ofloxacin.
• The prevalence of erythromycin-resistant GAS did not significantly change during the study period.

Conclusions:

• Penicillin and beta-lactams remain effective treatment options for Group A Streptococcus infections.
• Continued monitoring of resistance to erythromycin, clindamycin, tetracycline, and ofloxacin is warranted.
• The stability of erythromycin resistance suggests a persistent challenge in managing GAS infections with this agent.